CMSC INforMS: FDA Approves MAVENCLAD® (Cladribine) Tablets
Tuesday, April 30, 2019
Posted by: Rachelle Ramirez
- MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment
- MAVENCLAD's unique mechanism may provide an important new option for patients with ongoing active disease
- MAVENCLAD demonstrated significant efficacy across key measures of disease activity
- Approval is based on clinical program consisting of more than 9,500 patient years of cladribine data and up to eight years of time on study
ROCKLAND, Mass., March 29, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved MAVENCLAD® (cladribine) tablets for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS). MAVENCLAD is the first and only FDA-approved treatment for RRMS and active SPMS that provides two years of proven efficacy with a maximum of 20 days of oral treatment, during a two-year period.
Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8485951-emd-serono-mavenclad-fda-approval/
Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of multiple sclerosis (MS), and MAVENCLAD is not recommended for use in patients with clinically isolated syndrome (CIS). The MAVENCLAD label includes a boxed warning for potential risk of malignancy and risk of teratogenicity. The label appropriately defines the relevant associated contraindications.
"Multiple sclerosis is the leading cause of non-traumatic disability in young and middle-aged adults," said Belén Garijo, CEO Healthcare and Member of the Executive Board of Merck KGaA, Darmstadt, Germany. "We feel privileged to introduce MAVENCLAD into clinical practice in the United States. MAVENCLAD opens a new way to treat MS – a treatment that requires a maximum of 20 days of oral therapy to deliver two years of efficacy to a patient. This approval is a testimony to our long-standing commitment to people living with MS."
"As an investigator in the clinical trial program, I am pleased MAVENCLAD will now be available to patients in the U.S. With short treatment courses with pills taken for no more than 10 days in a year and no injections or infusions, MAVENCLAD is an efficacious new treatment option for MS," said Thomas Leist, M.D., PhD, Director, Comprehensive Multiple Sclerosis Center at Jefferson University Hospitals, Philadelphia, PA. "Nearly one million individuals are afflicted with MS in the U.S. alone, according to a recent National MS Society sponsored study. MAVENCLAD is a welcome new oral treatment option for this heterogeneous and often unpredictable disease."
Eighty-five percent of people living with MS are initially diagnosed with RRMS, characterized by attacks of new or increasing neurological symptoms. Most people with RRMS will eventually transition to a secondary progressive course in which there is a progressive worsening of neurologic function over time.1 SPMS can be further characterized at different points as either active (with relapses and/or evidence of new magnetic resonance imaging [MRI] activity) or not active.
"The FDA approval of MAVENCLAD is excellent news for people living with RRMS and active SPMS. MAVENCLAD offers a new and effective option for some of those patients with an oral dosing schedule unlike any other treatment currently available," said June Halper, CEO of the Consortium of MS Centers (CMSC). "People living with MS should have the ability to work with their clinician to choose a treatment with a dosing schedule that supports their lifestyle. CMSC congratulates EMD Serono for their dedication to bring MAVENCLAD to the U.S. as the first short-course oral treatment option for the community."
In the clinical trial program, 1,976 patients received therapy for a total of 9,509 patient years, of which the mean time on study including follow-up was approximately 4.8 years and 24% of the follow-up was for eight years. MAVENCLAD demonstrated clinical efficacy across key measures of disease activity, such as annualized relapse rate (ARR), disability progression and MRI activity:
- Patients experienced a 58% relative reduction in the ARR with MAVENCLAD compared to placebo (0.14 vs. 0.33, p<0.001).
- 81% of patients were free of relapses after two years of short-course oral treatment with MAVENCLAD, compared to 63% of patients who received placebo (p<0.05).
- Patients treated with MAVENCLAD had a 33% reduction in risk of 3-month confirmed disability progression as measured by Expanded Disability Status Scale (EDSS) compared to placebo (p<0.05).
- Patients taking MAVENCLAD experienced a lower median number of T1-weighted gadolinium-enhanced brain lesions and new or enlarging T2 brain lesions compared to patients with placebo (0 vs. 0.33 and 0 vs. 0.67, p<0.001).
The most common (>20%) adverse reactions reported in the pivotal Phase III study, CLARITY, were upper respiratory tract infection, headache and lymphopenia. Serious adverse reactions reported in the clinical program included malignancies (0.27 events per 100 patient-years) in MAVENCLAD treatment arms, compared to placebo patients (0.13 events per 100 patient-years), and herpes zoster infections (2.0% vs. 0.2%) and oral herpes (2.6% vs. 1.2%).
Following the administration of two treatment courses, additional courses of MAVENCLAD are not to be administered. Re-treatment with MAVENCLAD during years three and four may further increase the risk of malignancy. The safety and efficacy of reinitiating MAVENCLAD more than two years after completing two treatment courses has not been studied.
EMD Serono is committed to helping support patients prescribed MAVENCLAD. Over the course of 16 years, the company's comprehensive patient support program in the U.S., MS LifeLines®, has had over four million touchpoints with patients, care partners, healthcare professionals and other stakeholders to support our goal of providing one-on-one assistance to U.S. patients prescribed an EMD Serono MS therapy. MS LifeLines is now expanding to help patients prescribed MAVENCLAD and offers personalized patient support, including assistance with navigating insurance questions and additional resources that may be able to assist patients who are uninsured or underinsured.
The U.S. approval of MAVENCLAD follows its approval in over 50 countries, including the European Union (EU) in August 2017.
For more information on MAVENCLAD, and prescribing information including the boxed WARNINGS, visit www.MAVENCLAD.com.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About MAVENCLAD® (cladribine) Tablets (10 mg)
MAVENCLAD, approved by the U.S. Food and Drug Administration (FDA) on March 29, 2019, is the first short-course oral therapy for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS). MAVENCLAD is not recommended for use in patients with clinically isolated syndrome (CIS) because of the risk of malignancy. Patients should follow healthcare provider instructions including cancer screening, contraception and blood tests. The approved dose of MAVENCLAD is 3.5 mg per kg body weight over two years, administered as one treatment course of 1.75 mg per kg per year, each consisting of two treatment weeks. The mechanism by which cladribine exerts its therapeutic effects in patients with multiple sclerosis has not been fully elucidated but is thought to involve cytotoxic effects on B and T lymphocytes through impairment of DNA synthesis, resulting in depletion of lymphocytes. MAVENCLAD causes a dose-dependent reduction in lymphocyte counts followed by recovery.
Because cladribine is cytotoxic, special handling and disposal instructions should be followed.
MAVENCLAD has been approved in over 50 countries, including the European Union (EU), Canada, Australia and Switzerland, for various relapsing MS indications. Visit www.MAVENCLAD.com for more information.
About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.3 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.
EMD Serono, Inc. and Multiple Sclerosis
For more than 20 years, EMD Serono has been relentlessly focused on understanding the journey people living with MS face in order to create a meaningful, positive experience for them and the broader MS community. However, there is still much that is unknown about this complex and unpredictable disease. EMD Serono is digging deeper to advance the science.
About EMD Serono, Inc.
EMD Serono - the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada - is engaged in the discovery, research and development of medicines for patients with difficult to treat diseases. The business is committed to transforming lives by developing and delivering meaningful solutions that help address the therapeutic and support needs of individual patients. Building on a proven legacy and deep expertise in neurology, fertility and endocrinology, EMD Serono is developing potential new oncology and immuno-oncology medicines while continuing to explore potential therapeutic options for diseases such as psoriasis, lupus and MS. Today, the business has approximately 1,300 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts. www.emdserono.com
1 National MS Society. Secondary progressive MS (SPMS). www.nationalmssociety.org/What-is-MS/Types-of-MS/Secondary-progressive-MS. Accessed March 2019.
SOURCE EMD Serono
The industry news information and articles are for informational purposes only, and are not intended to represent any trends, partnerships, commitments, or research of the Consortium of MS Centers or any of it's members in any way whatsoever, nor should any party be libel in any way to the reader or to any other person, firm or corporation reading this industry news section. Although the CMSC site includes links providing direct access to other Internet sites, CMSC takes no responsibility for the content or information contained on those other sites, and does not exert any editorial or other control over those other sites. CMSC is providing information and services on the Internet as a benefit and service in furtherance of CMSC's nonprofit and tax-exempt status. CMSC makes no representations about the suitability of this information and these services for any purpose.